EMBioSys

The Future of Cancer Therapy is Wearable.

https://wefunder.com/embiosys

Total raised on Wefunder: 0

Total investors: 0

Quick facts

  • Efinia™ is a novel, patented, scalable platform technology representing a large market opportunity
  • $2.65 Million in non-dilutive funding awarded to date from the National Cancer Institute
  • Experienced cross-functional team and business partners
  • Compelling pre-clinical evidence and peer reviewed publications
  • Excellent safety profile: Non-invasive, low power, no adverse events in pre-clinical studies
  • Standard distribution path from demand...to order...to patient
  • Product design & manufacturing activities completed with inventory to support human clinical trials
  • Clear clinical development plan to reach product launch in an area of high unmet medical need

Team profiles

Featured investor profiles

EMBioSys

The Future of Cancer Therapy is Wearable

EARLY BIRD TERMS: $165,500 LEFT

$34,500

of a $50,000 goal
INVESTMENT TERMS
Future Equity
 $10.5M  $8.5M post-money valuation cap
Early Bird Bonus: The first $200K of investments will be in a SAFE with a $8.5M valuation cap

What Investors Say

LEAD INVESTOR
Invested $5,000 this round
Cancer treatment has advanced tremendously in recent years, yet many patients still face therapies that are physically and emotionally difficult to endure. I am motivated by solutions that not only improve clinical outcomes, but also the patient’s quality of life during treatment. Efinia’s approach of delivering cancer therapy in the form of a non-invasive wearable offers patients a fundamentally different experience. The potential to provide an impactful cancer treatment without relying solely on drugs or invasive procedures is what convinced me that this mission is unique. I am especially encouraged that EMBioSys recently received a Direct-to-Phase II award from the National Cancer Institute, which speaks to the rigor of the team’s scientific approach and their thoughtful engagement with the clinical and regulatory pathway. I’m leading this round because I believe patients deserve better options, and because this impressive and dedicated team is developing technology with both compassion and precision in mind.
What People Say